Critical Care

official impact factor 4.60
Search for
Advanced search
Critical Care
Tools

This article is part of the supplement: Severe sepsis and drotrecogin alfa (activated)

Highly Access

Practical aspects of treatment with drotrecogin alfa (activated)

Luigi Camporota and Duncan Wyncoll*

Critical Care 2007, 11(Suppl 5):S7 doi:10.1186/cc6158

Accesses  

  • Last 30 days: 45 accesses
  • Last year: 702 accesses
  • All time: 6632 accesses

Cited by

BioMed Central: 3 citations

Research   Open Access Highly Accessed

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

M Zia Sadique, Richard Grieve, David A Harrison, Brian H Cuthbertson, Kathryn M Rowan Critical Care 2011, 15:R228 (26 September 2011)

Abstract | Full text | PDF | PubMed

Commentary   Free

Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...

Manu Shankar-Hari, Duncan Wyncoll Critical Care 2010, 14:188 (9 August 2010)

Abstract | Full text | PDF | PubMed

Introduction   Free Highly Accessed

Introduction: severe sepsis and drotrecogin alfa (activated)

Antonio Artigas, Claude D Martin Critical Care 2007, 11(Suppl 5):S1 (19 December 2007)

Full text | PDF | PubMed

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations